Results 41 to 50 of about 47,826 (189)

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

npj Breast Cancer, 2017
Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast
Jo Anne Zujewski, Lawrence Rubinstein
doaj   +1 more source

Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.

PLoS ONE, 2013
BackgroundCapecitabine has proven effective as a chemotherapy for metastatic breast cancer. Though several Phase II/III studies of capecitabine as neoadjuvant chemotherapy have been conducted, the results still remain inconsistent.
Qiuyun Li, Yi Jiang, Wei Wei, Huawei Yang, Jianlun Liu   +4 more
doaj   +1 more source

Targeted drug delivery of capecitabine to mice xenograft gastric cancer by PAMAM dendrimer nanocarrier [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Aims: This study used an animal xenograft model of gastric cancer induction to investigate the therapeutic effects of capecitabine polyamidoamine (PAMAM) dendrimer complex against cancer and its potential side effects.
Sharareh Jafari, Fatemeh Nabavizadeh, Jalal Vahedian, Mehdi Ardestani, Hedayat Samandari, Ali Mehrjerdi   +5 more
doaj   +1 more source

DPYD and UGT1A1 Genotype‐Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant‐Specific Impact on Treatment Intensity and Toxicity

International Journal of Cancer, EarlyView.
Pre‐treatment DPYD and UGT1A1 genotyping is increasingly used to prevent fluoropyrimidine‐ and irinotecan‐related toxicity, but variant‐specific real‐world effects remain unclear. In an unselected cohort of cancer patients with actionable genotypes, genotype‐driven dosing improved safety while preserving treatment exposure in high‐risk DPYD c.1905+1G>A
Martina Gambron, Elena Peruzzi, Samantha Perfler, Marcella Montico, Riccardo Cecchin, Elena De Mattia, Michele Spina, Camilla Lisanti, Serena Corsetti, Luisa Foltran, Fabio Puglisi, Rossana Roncato, Erika Cecchin   +12 more
wiley   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI‐SAFRADJU‐2501)

International Journal of Cancer, EarlyView.
ABSTRACT The recommended adjuvant chemotherapy (adj‐ChT) regimen for resected biliary tract cancers (BTC) is capecitabine (Cape); yet, the recommendation is based on limited evidence. Although varied adj‐ChTs have been employed in practice, robust real‐world data is scarce. We conducted a national, multicenter, hospital‐based registry study to evaluate
Erman Akkus, Mehmet Kayaalp, Müzeyyen Aslı Ergözoğlu, Ilgın Koç Kuş, Doğan Bayram, Bilgeşah Kılıçtaş, Emel Ayvaz Güneyin, Ali Kalem, Haydar Temizyürek, Mehmet Mutlu Çatlı, Mehmet Sinan Akarca, Maral Martin Mıldanoğlu, Görkem Turhan, Mahmut Kara, Hacı Arak, Feyza Arslan Tan, Burak Paçacı, Berkay Yeşilyurt, Orhun Akdoğan, Emine Bihter Çetin, Selahattin Çelik, Fatma Keskin Uzundere, Elif Şahin, Zehra Sadak Öcal, Lamia Şeker Can, Bahadır Köylü, Mehmet Cem Fidan, Esmanur Kaplan Tüzün, Teoman Şakalar, Elif Sertesen Çamöz, Haydar Çağatay Yüksel, Onur Yazdan Balçık, Pınar Peker, Mehmet Yılmaz, Şeymanur Ala Enli, Erdem Kölemen, Sibel Oyucu Orhan, Yakup Düzköprü, Mustafa Ersoy, Tuğba Akın Telli, Mesut Yılmaz, Yusuf İlhan, Atila Yıldırım, Ramazan Coşar, Müslih Ürün, Arif Hakan Önder, Murat Araz, Ertuğrul Bayram, Havva Yeşil Çınkır, Ali Alkan, Mustafa Gürbüz, Nilüfer Avcı, Fatma Paksoy Türköz, İsmail Oğuz Kara, Fatih Köse, İlkay Tuğba Ünek, Ahmet Bilici, Öznur Bal, Şuayib Yalçın, Lorenza Rimassa, Hatime Arzu Yaşar   +60 more
wiley   +1 more source

Management of severe capecitabine-induced corneal toxicity

American Journal of Ophthalmology Case Reports
Purpose: To describe the clinical presentation and management of severe capecitabine-induced corneal toxicity. Observations: A 71-year-old woman presented with severe bilateral vision loss. Four months earlier, capecitabine was initiated for a metastatic
Mathieu Heyvaert, Hannelore Denys, Jo Van Dorpe, Dimitri Roels   +3 more
doaj   +1 more source

The Prognostic Value of EDRIC and Its Association With Radiation‐Induced Lymphopenia in Patients With Esophageal Cancer Undergoing Radical Radiotherapy: A Single‐Center Chinese Study

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This study aimed to evaluate the predictive value of the estimated dose of radiation to immune cells (EDRIC) in patients with esophageal cancer receiving radical radiotherapy. We retrospectively reviewed the data of patients with esophageal cancer who underwent definitive radiotherapy at our institution.
Yue Ke, Chen Yang, Yu‐Xing Li, Xiao‐Xiao Liu, Xiao Liu, Jia‐Min Gao, Hong‐Bing Ma   +6 more
wiley   +1 more source

Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model

Acta Medica Iranica, 2016
Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with azoxymethane, a carcinogen agent, and then investigated the
Fatemeh Nabavizadeh, Hafseh Fanaei, Alireza Imani, Jalal Vahedian, Fahimeh Asadi Amoli, Jamal Ghorbi, Hamid Sohanaki, Seyed Mehdi Mohammadi, Ravieh Golchoobian   +8 more
doaj  

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study

Breast
Purpose: To determine the beneficiaries of capecitabine in patients with triple-negative breast cancer (TNBC) who failed to achieve pathological complete response (pCR) by analyzing the efficacy of the drug in different HER2 statuses and TNM stages ...
Youzhao Ma, Mingda Zhu, Jingyang Zhang, Dechuang Jiao, Yangyang Hou, Xiuchun Chen, Zhenzhen Liu   +6 more
doaj   +1 more source